Physician profile
Mark A Manegold
NPI 1396749891
$5,225.15
in general payments reported to CMS, 2019-2025
28 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $550 · 2021: $1,002 · 2022: $1,163 · 2023: $612 · 2024: $203 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,963.70 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $911.42 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $512.69 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $433.66 | 2019-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $226.13 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $187.30 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $176.77 | 2019-2023 | Dificid |
| Pfizer INC. | $119.28 | 2019-2025 | |
| Gilead Sciences, INC. | $81.09 | 2019-2020 | |
| Braintree Laboratories, INC. | $77.13 | 2022-2023 | Sutab |
| Concordia Pharmaceuticals INC. | $66.22 | 2019 | |
| Olympus America INC. | $50.18 | 2025 | Olympus, Single Use Repositionable Clip |
| Redhill Biopharma INC. | $47.07 | 2020-2021 | |
| Romark Laboratories, Lc | $46.40 | 2019 | |
| Daiichi Sankyo INC. | $46.20 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $43.58 | 2021-2023 | |
| Qol Medical, LLC | $40.62 | 2023-2025 | Sucraid |
| Madrigal Pharmaceuticals | $30.20 | 2024 | Resmetirom |
| Allergan, INC. | $25.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.37 | 2022 | |
| Ardelyx, INC. | $16.03 | 2024 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $15.84 | 2025 | Zilretta, Exparel |
| Novo Nordisk INC | $15.36 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $15.24 | 2020 | |
| Evoke Pharma, INC. | $14.04 | 2022 | |
| Celgene Corporation | $13.64 | 2022 | |
| Genzyme Corporation | $12.74 | 2023 | |
| Alfasigma USA, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Manegold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.